Donepezil for Alzheimer's: What Chinese Studies Reveal About Efficacy and Safety
"Uncover the latest insights on donepezil's effectiveness in treating Alzheimer's in Chinese patients, and how it compares to Western findings."
Alzheimer's disease (AD) is a growing concern in China, affecting a significant portion of the aging population. With prevalence rates on the rise, understanding effective treatments is crucial. However, many patients are diagnosed in later stages, highlighting the need for early and effective interventions.
Donepezil, an acetylcholinesterase inhibitor (AChEI), is a commonly used medication for managing AD symptoms. It works by increasing the levels of acetylcholine, a neurotransmitter vital for memory and cognitive function. While donepezil's effectiveness is well-established, its specific impact on Chinese patients requires careful examination.
This article delves into recent research focusing on donepezil's efficacy and safety in treating Alzheimer's disease among Chinese patients. We'll explore how donepezil compares to other treatments, factors influencing its response, and potential differences compared to Western populations.
The Current Burden of Alzheimer’s Disease
Alzheimer’s disease remains an important health concern, and donepezil is used as one approach to managing symptoms. Its potential value is generally discussed in terms of cognitive function, daily functioning, and behavior. However, the scale of its current population impact and precise treatment outcomes require careful interpretation of study-specific evidence.
Established Treatment Approach
Donepezil is commonly evaluated through measures of cognition, functional ability, and behavior. Treatment effects may vary according to disease stage, dosage, treatment duration, and individual tolerability. These limitations mean that evidence about benefit should not be generalized beyond the populations and outcomes studied.
From Early Trials to Dose Comparisons
Research on donepezil has developed from long-term open-label extension work and randomized trials to later dose-focused reviews. In one early-stage Alzheimer disease study, 96 patients received donepezil, beginning at 5 mg per day for six weeks before forced escalation to 10 mg per day, while 57 received placebo; the primary efficacy measure was the modified Alzheimer Disease Assessment Scale-cognitive subscale. A 2024 meta-analysis subsequently compared 5 mg/day and 10 mg/day, reporting cognitive improvement with both doses and greater efficacy with 10 mg/day. These studies illustrate the field’s progression from establishing treatment effects to examining dose-related differences.
How Effective is Donepezil for Chinese Patients?
A comprehensive review of studies, including clinical trials and well-designed research, reveals that donepezil has demonstrated effectiveness and safety in Chinese AD patients. These studies suggest improvements in cognitive function and a potential impact on key AD biomarkers.
- Cognitive Function: Donepezil has been shown to improve cognitive function, as measured by tests like the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog).
- Daily Living Activities: Patients on donepezil exhibited improvements in their ability to perform daily tasks, indicating a better quality of life.
- Global Function: Overall, donepezil contributes to better global function, reflecting a comprehensive improvement in patients' condition.
Recent Evidence on Donepezil Strategies
Recent research has examined both donepezil dosage and combination treatment. A 2024 meta-analysis reported that 5 mg/day and 10 mg/day improved cognitive function in patients with dementia, with 10 mg/day appearing more efficacious. Updated meta-analysis work has also focused on whether combining donepezil with memantine offers advantages over donepezil monotherapy. In addition, a single-center retrospective analysis studied donepezil combined with rehabilitation training and its relationship to nerve growth factor and brain-derived neurotrophic factor.
Limits of the Evidence
Evidence about donepezil should be interpreted cautiously because treatment effects can differ across patients and study designs. Retrospective and single-center analyses may provide useful signals but cannot establish the same level of certainty as randomized trials. Differences in dosage, disease stage, outcome measures, and treatment combinations can also make findings difficult to compare directly.
Comparing Treatment Options
Comparisons of donepezil commonly involve different doses, monotherapy versus combination therapy, or medication paired with rehabilitation. Such comparisons may address distinct questions rather than identify one universally superior approach. Meaningful interpretation therefore depends on whether the studies measure cognition, function, behavior, biological markers, or a combination of outcomes.
What Does This Mean for Alzheimer's Treatment?
Donepezil stands as a valuable treatment option for Chinese patients with Alzheimer's disease, offering improvements in cognitive function, daily activities, and overall well-being. However, the importance of personalized treatment approaches cannot be overstated. Genetic factors and individual patient characteristics can influence treatment outcomes, necessitating tailored strategies.
What the Evidence Suggests
Taken together, the available evidence supports viewing donepezil as a symptom-management treatment whose effects should be assessed across several domains. Cognitive outcomes are important, but functional ability and behavior also matter when judging clinical value. The evidence base remains dependent on study design, dose, treatment duration, and the characteristics of the people studied.
Duration and Changing Benefits
Future discussion of donepezil is likely to focus not only on whether it works, but also on how long its benefits remain meaningful. ScienceInsights reports that donepezil can help manage dementia symptoms for years, while emphasizing that the nature of its benefits may shift over time. This perspective highlights the need to examine treatment effectiveness longitudinally rather than treating benefit as a fixed outcome.
Multiple Domains of Alzheimer’s Care
An evidence-based review reports strong evidence that donepezil has efficacy across the three major domains of Alzheimer’s disease symptoms: functional ability, behavior, and cognition. This broader framing is important because treatment value cannot be captured by cognitive testing alone. It also underscores the systemic challenge of evaluating and supporting outcomes that affect everyday life as well as clinical assessments.
Effects on Daily Life
A 2026 review describes donepezil’s effectiveness in mild, moderate, and even severe Alzheimer’s disease in relation to patient behavior, daily activities, and cognitive performance. These domains connect treatment research with the experiences of patients and caregivers. Because the reported effects span symptoms and everyday functioning, real-world assessment should consider more than cognitive performance alone.
Further research is essential to fully understand the nuances of donepezil's impact on Chinese patients. Exploring the influence of genetic variations and comparing donepezil to other treatments will help refine treatment guidelines and optimize patient care.
Ultimately, a comprehensive understanding of donepezil's effects, combined with personalized approaches, holds the key to enhancing the lives of individuals and families affected by Alzheimer's disease in China and worldwide.